When a physician decides to explore the sale of their practice, one of the first and most consequential decisions they face isn’t about price. It’s about buyer type. The two most prominent categories of acquirers in today’s market — private equity-backed platforms and health systems — operate with fundamentally different motivations, structures, and expectations. The transaction they offer you looks different, the employment relationship that follows looks different, and the long-term implications for your professional life and financial outcome look different.
Neither is categorically better. The right buyer for your practice depends on your specialty, your market, your financial goals, and — perhaps most importantly — your honest assessment of what you want your professional life to look like after closing. What matters is that you understand the distinction clearly before you’re sitting across the table from either one.
Understanding Who You’re Actually Dealing With
Before getting into the mechanics of how these transactions differ, it’s worth understanding the underlying logic of each buyer type, because that logic shapes everything about how they approach an acquisition and what they want from you afterward.
Private equity firms raise capital from institutional investors — pension funds, endowments, sovereign wealth funds — with the explicit goal of generating returns over a defined investment horizon, typically five to seven years. In physician practice M&A, PE firms generally operate through a platform model: they acquire an initial practice in a given specialty and geography, use it as a foundation to acquire additional practices, build a larger consolidated organization, and eventually sell that organization to a larger PE firm or strategic acquirer at a higher multiple than they paid to build it. The business model depends on growth, operational improvement, and a successful exit.
Health systems are acquiring for fundamentally different reasons. They are not building toward an exit. Their interest in physician practices is strategic — securing referral networks, expanding geographic footprint, adding service lines, and increasingly, protecting market position against PE-backed competitors who are consolidating the physician landscape around them. A health system acquiring your practice intends to integrate it into a larger clinical and operational enterprise and retain it indefinitely. There is no investment horizon, no planned exit, and no secondary transaction on the horizon for you to participate in.
That said, a growing number of health systems are approaching physician practice acquisitions through a more sophisticated structure than simple employment — one that blurs the traditional line between PE-style ownership and health system integration. Joint ventures, discussed in detail below, represent an increasingly common middle path in certain markets and specialties, and they change the calculus of a health system transaction in ways that are worth understanding from the outset.
That difference in underlying motivation — financial return vs. strategic integration — drives virtually every other difference between the two buyer types.
Deal Structure and Economics
The financial structure of a PE transaction and a health system acquisition are different enough that comparing headline purchase prices without understanding structure is nearly meaningless.
In a PE transaction, the purchase price is typically expressed as a multiple of EBITDA and is paid in a combination of cash at closing and rollover equity — a meaningful ownership stake in the acquiring platform that you retain as a continuing shareholder. The rollover component, often representing fifteen to thirty percent of the total consideration, is not a compromise or a concession. It is, for many physicians, the most significant wealth-creation opportunity in the entire transaction. If the platform performs well and exits at a higher multiple than it paid for your practice — which is the explicit goal — your rollover equity can return two, three, or more times its original value. Physicians who have participated in successful PE platform exits often describe the “second bite of the apple” as ultimately exceeding the initial cash payment.
The tradeoff is that rollover equity is illiquid, its value is uncertain, and it is often subordinate to the PE firm’s preferred return in the capital structure. You are a minority shareholder in an organization controlled by sophisticated financial investors with their own timeline and agenda.
Health system transactions in their traditional form are typically cleaner in structure — often closer to a straightforward asset purchase with a defined payment for the practice’s goodwill, tangible assets, and patient relationships. You receive cash, and the transaction is largely complete. There is generally no rollover equity component and therefore no ongoing financial upside tied to the performance of the acquiring organization. What you receive is what you receive.
Health system compensation post-closing is usually structured around a base salary plus a productivity component — commonly wRVU-based — with benefits including malpractice coverage, retirement contributions, and health insurance. The total compensation picture can be competitive, but it is a different financial model than the equity-forward structure of a PE transaction, and the upside is capped in a way that PE rollover equity is not.
The Joint Venture: A Third Path Worth Understanding
In select markets and specialties, health systems are beginning to offer a transaction structure that doesn’t fit neatly into either the traditional acquisition or the PE model — the joint venture. It’s worth understanding what this structure is, why health systems are offering it, and what it means for physician sellers who encounter it.
In a joint venture, rather than acquiring your practice outright, the health system partners with your physician group to create a new jointly owned entity — typically with the health system holding a majority interest and the physician group retaining a meaningful minority stake, often in the range of twenty to forty percent. The practice’s clinical operations, assets, and patient relationships transfer into the new entity, and both parties share in its ongoing economics according to their respective ownership positions.
Why health systems are offering this
The motivations are partly financial and partly relational. From a financial standpoint, a joint venture allows a health system to acquire strategic alignment with a physician group without absorbing the full cost of an outright acquisition — particularly relevant in specialties where valuations have risen considerably. From a relational standpoint, health systems have learned, sometimes the hard way, that physicians who retain equity in their practice behave differently than physicians who have been fully bought out. Ownership creates alignment, and health systems that have struggled with productivity and retention in fully employed physician groups are increasingly interested in structures that preserve that ownership mentality.
What it means for physician sellers
A joint venture occupies interesting territory between a traditional health system acquisition and a PE transaction. Like a PE deal, it allows physicians to retain an ongoing equity stake with the potential for future appreciation — particularly if the joint venture grows, adds partners, or becomes an acquisition target itself. Like a health system transaction, it provides institutional resources, infrastructure, and the removal of full ownership responsibility without handing control to a financial sponsor with a fixed exit timeline.
The economics of a joint venture require careful analysis. The upfront cash consideration is typically lower than in an outright acquisition — you are, after all, retaining partial ownership rather than selling everything. The long-term value of that retained stake depends on how the joint venture performs, how distributions are structured, and what rights the physician partners have if the health system eventually seeks to acquire the remaining interest or if the physicians wish to exit. Those terms are negotiable, and negotiating them well requires advisors who understand both the healthcare regulatory environment and the deal mechanics of joint venture structures.
Joint ventures are not universally available — they tend to emerge in markets where health systems face competitive pressure from PE-backed consolidators and need a differentiated offer to attract physician partners. If you’re in a market where this structure is being offered, it signals both genuine health system interest and a competitive dynamic that, managed properly, can be used to your advantage.
Autonomy and Practice Culture
This is the dimension that physicians consistently underestimate during a transaction and consistently wish they had thought about more carefully afterward.
PE-backed platforms vary considerably in how much operational and clinical autonomy they extend to physician partners, and those differences are not always apparent from the initial conversations. The best PE-backed platforms are genuinely physician-led and make meaningful investments in preserving the culture and clinical environment that made acquired practices successful in the first place. They understand that the asset they’re acquiring is inseparable from the physicians who built it, and they manage accordingly.
Others are more aggressive in their operational integration — centralizing billing, standardizing clinical protocols, optimizing scheduling for throughput, and making decisions about staffing and overhead that physicians historically made for themselves. None of these are inherently unreasonable from a business perspective, but they can feel jarring to physicians who have spent careers practicing on their own terms.
The honest answer is that clinical autonomy within a PE platform depends heavily on the specific sponsor, the specific platform, and the specific deal terms you negotiate. It is not a given, and it is not uniform across the market. Evaluating it requires more than listening to what a buyer tells you about their physician-friendly culture — it requires talking to physicians who joined that platform two or three years ago and asking them candidly whether the promises made during the deal process matched the reality afterward.
Health systems present a different autonomy profile. The integration tends to be more immediate and more complete. You are joining a large organization with established protocols, reporting structures, credentialing requirements, and administrative processes that predate your arrival and will not be adjusted to accommodate your preferences. The practice you built will, to varying degrees, be absorbed into that organization’s operational framework.
Compensation committees, productivity benchmarks, call schedule policies, and decisions about staffing and facilities are made at an organizational level, not a practice level. Physicians who have operated independently for most of their careers often find this adjustment more significant than they anticipated. The removal of administrative burden — which is real and often welcome — comes alongside a corresponding reduction in decision-making authority that can take some time to reckon with.
The joint venture structure modifies this autonomy profile in meaningful ways. Because physician partners retain an ownership stake in the new entity, governance rights — including physician representation on the joint venture’s board or operating committee — are often negotiable as part of the deal structure. Physicians who secure meaningful governance participation can retain a voice in operational and clinical decisions that would otherwise move entirely to the health system upon a traditional acquisition. How much that governance participation translates into real decision-making influence, versus a nominal seat at a table where major decisions have already been made, varies by structure and by health system. It is worth probing carefully and documenting specifically in the joint venture agreement.
The Employment Agreement: Where the Real Differences Live
Regardless of buyer type, the employment agreement you sign at closing will govern your professional life for the years that follow, and its terms matter enormously. This is an area where physicians frequently focus too much on the purchase price and too little on the document that determines what happens after the check clears.
Both buyer types will ask you to sign a post-closing employment agreement with a defined term, compensation structure, non-compete provisions, and termination rights. The specifics vary significantly.
Non-compete clauses tend to be more aggressively drafted in PE transactions because the buyer is protecting a platform investment across potentially dozens of acquired practices. Geographic scope, duration, and carve-outs for existing patient relationships are all negotiable — but they require active, informed negotiation to achieve favorable terms. Signing the initial draft without pushback in this area is a mistake we see too often.
Termination rights deserve careful attention in both contexts. Understanding whether you can be terminated without cause, what notice is required, who is responsible for malpractice tail coverage upon termination, and what happens to your compensation structure if the platform is acquired by a new sponsor — these are not theoretical questions. They are practical ones that determine your options if the post-closing relationship doesn’t unfold as expected.
Compensation structure post-closing is another area where the initial offer is rarely the best available outcome. Whether you’re entering a PE platform or a health system employment arrangement, the wRVU thresholds, base salary, bonus structure, and benefit package are negotiable to a degree that most physicians don’t realize — particularly when they have representation making that case on their behalf.
Joint venture agreements introduce an additional layer of documentation beyond the employment agreement — the operating agreement governing the joint venture entity itself. This document defines ownership percentages, distribution priorities, buy-sell provisions, rights of first refusal, and the terms under which either party can exit the arrangement. It is often as consequential as the employment agreement and receives far less attention from physicians during a transaction. Understanding what happens to your ownership stake if the health system decides to acquire the remaining interest — including how your minority interest will be valued and on what timeline — is not a hypothetical consideration. It is a near-certainty in most joint venture structures, and the terms governing that eventual buyout deserve as much scrutiny as anything else in the deal.
Timeline and Process
The transaction process itself differs between buyer types in ways that affect both the experience and the outcome.
PE-backed platform acquisitions tend to move faster when there is genuine buyer interest. PE sponsors are experienced deal-makers with dedicated M&A teams, established due diligence processes, and clear decision-making authority. A motivated PE buyer can move from initial conversation to letter of intent in weeks, and from LOI to closing in ninety to one hundred twenty days in straightforward transactions, though complex deals take longer.
Health system acquisitions often move more slowly, particularly in the early stages. Health systems operate with more institutional process — board approvals, legal review committees, compliance evaluations — and the individuals you’re meeting with across the table may not have the unilateral authority to move quickly even if they want to. What feels like enthusiasm and momentum on the buyer side can stall for reasons that have nothing to do with your practice. Patience is often required, and building that expectation into your timeline planning matters.
When One Buyer Type Makes More Sense Than the Other
There is no universal right answer, but there are circumstances where one buyer type tends to align better with a physician’s situation and goals.
A PE transaction tends to make more sense when the physician is mid-career — perhaps in their mid-forties to late fifties — with meaningful years of productive practice ahead, appetite for the financial upside of rollover equity, and tolerance for the dynamics of operating within a PE-owned platform. It also tends to favor specialties with strong platform economics — procedure-heavy, fee-for-service, with payor mix weighted toward commercial insurance.
A traditional health system transaction tends to make more sense when the physician’s primary goals are transition and simplicity — when the objective is to shed the administrative and financial responsibilities of ownership, integrate into a stable institutional environment, and practice medicine with less operational noise. It also makes more sense in markets where PE interest in a given specialty is limited, or where the physician’s referral relationships and patient base are deeply embedded in a health system’s clinical network.
A joint venture with a health system occupies a distinct position in this framework and tends to make the most sense for physician groups that want ongoing equity participation and some degree of retained governance, but prefer the stability and mission alignment of a health system partner over the financial dynamics of a PE sponsor. It is also worth considering when a health system is the dominant strategic acquirer in a given market and a traditional full acquisition is the likely alternative — in that context, a joint venture may be the best available path to retaining meaningful equity upside within a transaction that is going to happen in some form regardless.
Many physicians find that a competitive process — one that brings PE buyers, health system acquirers, and where applicable, joint venture structures to the table simultaneously — produces the clearest picture of where the market actually values their practice. The tension between buyer types and transaction structures can be a powerful negotiating tool, and understanding the full universe of available options is almost always preferable to entering a conversation with just one.
The Question Beneath the Question
When physicians ask us whether they should sell to private equity or a health system, what they’re often really asking is a more fundamental question: what do I want the next chapter of my professional life to look like?
That question deserves a serious, unhurried answer before a transaction process begins — not after an LOI is signed and a preferred buyer is selected. The financial terms of a transaction are recoverable from in ways that a poorly chosen post-closing employment environment simply isn’t. Physicians who have done this thoughtfully — who entered a transaction knowing clearly what they were optimizing for and what tradeoffs they were prepared to accept — consistently report better outcomes, financial and otherwise, than those who focused primarily on the headline number.
If you’re in the early stages of thinking through these questions, we’d welcome a conversation. Understanding your options clearly, without obligation or pressure, is the right starting point — and it’s exactly what we’re here to help with.
Alexander Price & Co.
Healthcare Transaction Advisory
info@alexanderpriceandco.com | www.alexanderpriceandco.com
The information contained in this post is intended for general informational purposes and does not constitute legal, tax, or financial advice. Physicians considering a practice transaction should consult with qualified legal and financial advisors in addition to an experienced transaction advisor.
